~~<i id='77CB913009'><strike id='77CB913009'><tt id='77CB913009'><pre id='77CB913009'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：focus 2025-09-05 11:27:52 - browse：343

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

Wikipedia

focus

leisure time

focus

Whatdifferencedoesadaymake?Whogetstohavegenetherapy?AndarebiotechstartupsOK?Wecoverallthatandmorethi

WSS

ActiGraph execs on goal of drug approvals with digital endpoints

An interview with Robert F. Kennedy Jr. on vaccines

ALS groups 'won't be played again' by the FDA, drug sponsors

Ukraine taking heavy casualties 10 weeks into its counteroffensive

RaDonda Vaught to speak at CommonSpirit event on patient safety

How to address the problem of discarded donor organs

focus

fashion

focus

Alkermes shareholders re

FDA approves first treatment for ultra

Virginia high school admissions case could be legal follow

Change Healthcare cyberattack outage could last weeks

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Guidelines to prevent youth baseball injuries need more muscle

Baltimore teen accused of firing into crowd during block party mass shooting

Peter Hotez and the public health issue of online harassment

House looks to weaken Medicare negotiation

focus

Medical device lobby: We're tired of waiting on Medicare coverage

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

RSV vaccines may be linked to small increased risk of developing GBS

House looks to weaken Medicare negotiation

Hilary may become 1st tropical storm to make landfall in California in 84 years

Wikipedia

focus

leisure time

focus